Savara: The Market May Be Overestimating Its FDA Risk
· seekingalpha.com
Savara (SVRA) is rated a speculative BUY at $4.72 with a $7 twelve-month price target, anticipating a pivotal FDA decision on November 22.
Eljaye W. Tellis is a medicinal chemistry Ph.D. candidate and biotech investor. He covers biotechnology and healthcare equities, applying a therapeutic discover...